Needham lifts Pacira BioSciences Inc. [PCRX] price estimate. Who else is bullish?

Pacira BioSciences Inc. [NASDAQ: PCRX] traded at a high on 08/04/20, posting a 0.71 gain after which it closed the day’ session at $55.28.

The results of the trading session contributed to over 1127432 shares changing hands. Over the past one week, the price volatility of Pacira BioSciences Inc. stands at 3.29% while the volatility over the past one month is 3.83%.

The market cap for PCRX stock reached $2.35 billion, with 42.03 million shares outstanding and 41.80 million shares in the current float. Compared to the average trading volume of 716.83K shares, PCRX reached a trading volume of 1127432 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Pacira BioSciences Inc. [PCRX]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PCRX shares is $61.54 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PCRX stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Needham have made an estimate for Pacira BioSciences Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on July 06, 2020. The new note on the price target was released on May 27, 2020, representing the official price target for Pacira BioSciences Inc. stock. Previously, the target price had yet another raise to $50, while Northland Capital analysts kept a Outperform rating on PCRX stock.

The Average True Range (ATR) for Pacira BioSciences Inc. is set at 2.25, with the Price to Sales ratio for PCRX stock in the period of the last 12 months amounting to 5.40. The Price to Book ratio for the last quarter was 6.21, with the Price to Cash per share for the same quarter was set at 7.49. Price to Free Cash Flow for PCRX in the course of the last twelve months was 40.33 with Quick ratio for the last quarter at 4.60.

How has PCRX stock performed recently?

Pacira BioSciences Inc. [PCRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.37. With this latest performance, PCRX shares gained by 1.88% in over the last four-week period, additionally plugging by 26.18% over the last 6 months – not to mention a rise of 28.14% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PCRX stock in for the last two-week period is set at 57.53, with the RSI for the last a single of trading hit 60.49, and the three-weeks RSI is set at 59.43 for Pacira BioSciences Inc. [PCRX]. The present Moving Average for the last 50 days of trading for this stock 49.97, while it was recorded at 53.72 for the last single week of trading, and 43.73 for the last 200 days.

Pacira BioSciences Inc. [PCRX]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Pacira BioSciences Inc. [PCRX] shares currently have an operating margin of +8.48 and a Gross Margin at +73.30. Pacira BioSciences Inc.’s Net Margin is presently recorded at -2.62.

Return on Total Capital for PCRX is now 5.41, given the latest momentum, and Return on Invested Capital for the company is -1.68. Return on Equity for this stock declined to -3.26, with Return on Assets sitting at -1.45. When it comes to the capital structure of this company, Pacira BioSciences Inc. [PCRX] has a Total Debt to Total Equity ratio set at 99.15. Additionally, PCRX Total Debt to Total Capital is recorded at 49.79, with Total Debt to Total Assets ending up at 42.35. Long-Term Debt to Equity for the company is recorded at 97.76, with the Long-Term Debt to Total Capital now at 49.09.

Reflecting on the efficiency of the workforce at the company, Pacira BioSciences Inc. [PCRX] managed to generate an average of -$18,178 per employee. Receivables Turnover for the company is 9.85 with a Total Asset Turnover recorded at a value of 0.55.Pacira BioSciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.60 and a Current Ratio set at 5.40.

Earnings analysis for Pacira BioSciences Inc. [PCRX]

With the latest financial reports released by the company, Pacira BioSciences Inc. posted 0.41/share EPS, while the average EPS was predicted by analysts to be reported at 0.35/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 17.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PCRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Pacira BioSciences Inc. go to 42.80%.

Insider trade positions for Pacira BioSciences Inc. [PCRX]

There are presently around $2,556 million, in the hands of institutional investors. The top three institutional holders of PCRX stocks are: BLACKROCK INC. with ownership of 6,823,110, which is approximately -2.59% of the company’s market cap and around 1.20% of the total institutional ownership; VANGUARD GROUP INC, holding 4,366,819 shares of the stock with an approximate value of $241.4 million in PCRX stocks shares; and RENAISSANCE TECHNOLOGIES LLC, currently with $136.44 million in PCRX stock with ownership of nearly 37.322% of the company’s market capitalization.

Positions in Pacira BioSciences Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 123 institutional holders increased their position in Pacira BioSciences Inc. [NASDAQ:PCRX] by around 5,646,405 shares. Additionally, 107 investors decreased positions by around 3,407,063 shares, while 36 investors held positions by with 37,185,669 shares. The mentioned changes placed institutional holdings at 46,239,137 shares, according to the latest SEC report filing. PCRX stock had 39 new institutional investments in for a total of 2,492,271 shares, while 32 institutional investors sold positions of 720,623 shares during the same period.

Share on facebook
Share on twitter
Share on linkedin
Share on skype
Share on reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam